ARE · Q4 2025 Earnings

Narrative arc: Q2 cautious operating quarter → Q3 broad capitulation across guidance, capital plan, and dividend → Q4 multi-year reset with structural bear-market framing and a 45% dividend cut.

The framing of the cycle moved from cyclical to structural. Q2 attributed weakness to macro persistence; Q3 admitted the capital-markets-to-leasing transmission had broken. Q4 declares the entire context: "In 2025, we witnessed the fifth year of a life science bear market." Joel's earlier comments framed a "four- to five-year recovery for life science broadly" with Peter qualifying that the two- to three-year recovery applies only to ARE's core markets, not the industry. Calling a fifth year of bear market while extending the recovery timeline four to five more years is not a soft-patch narrative — it's a multi-year reset for a thesis that had spent the prior decade priced as secular growth.

The development pipeline went from strategic engine to strategic liability. Q2 framed 2027 redevelopment as being reviewed for "alternative lower-cost investment opportunities." Q3 moved to active curtailment of the $4.2B land bank with willingness to stop capitalizing interest mid-project. Q4 escalates again: "we are evaluating the go-forward business strategy for four additional projects that are currently under construction and have significant remaining capital needs." Evaluating exits on projects already under construction — i.e., where capital is sunk and impairment risk is highest — is what generated the $1.45B Q4 impairment. The fact that more such reviews are open implies more impairments are possible.

The leasing recovery narrative inverted again. Q2: venture funding tailwinds. Q3: VC funding insufficient on its own. Q4: explicit admission that the binding constraint is the public market. Hallie noted "venture funds have raised the lowest amount of dollars in the last decade" and that the active VCs are funding "commercial or near commercial companies, which don't typically drive lab space needs." Joel: "we need to see that public biotech sector contribute to the leasing pipeline in order for it to really start to turn around." This is a structural diagnosis — until the IPO window reopens for pre-commercial biotech, the lab-space demand pool stays constrained regardless of what XBI does.

Pricing-power compression now sits in the cash spreads. Q3 admitted free rent was rising; Q4 puts the cash-basis renewal spread guide at outright negative -12.0% to -4.0%. Peter's commentary that "rental rates are stable" but "net effectives" require improvement is the same admission Q3 made in qualitative form, now hardcoded into the 2026 guide. A REIT guiding to negative cash spreads on its renewal book has acknowledged that the in-place rent roll is above market.

Capital allocation moved from opportunistic to mandatory. Q3 withdrew the FY25 disposition target. Q4 introduces a $2.1B–$3.7B FY26 program (mid $2.9B), of which 65%–75% is non-core and land. Combined with $1.45B of Q4 impairments, four more under-construction projects under strategic review, and a 45% dividend cut to preserve ~$410M of annual liquidity, the message is that the portfolio is being repositioned under stress, not optimized at the margin.